瑞舒伐他汀10mg·d^(-1)对国人调脂作用有效性和安全性的Meta分析

Lipid-regulatory Efficacy and Safety of Rosuvastatin (10mg·d^(-1)) for Chinese Population:A Meta-analysis

目的:评价瑞舒伐他汀10mg·d-1对国人调脂作用的有效性和安全性。方法:从万方数据库、中国期刊网全文数据库、维普全文电子期刊中检索2001～2008年的相关文献,比较应用瑞舒伐他汀10mg·d-1前、后血脂的变化,并利用RevMan4.2对数据进行Meta分析,同时对其安全性作出评价。结果:5项研究共346例患者入选,经瑞舒伐他汀10mg·d-1治疗后低密度脂蛋白胆固醇(LDL-C)平均降低1.71mmol·L-1,总胆固醇(TC)平均降低1.98mmol·L-1,高密度脂蛋白胆固醇(HDL-C)平均升高0.17mmol·L-1,甘油三酯(TG)平均降低0.79mmol·L-1。共报道了54例不良事件,主要为轻微的上呼吸道感染症状、轻微背痛、轻微乏力和轻微胃肠道不适,均未出现严重的不良反应。结论:瑞舒伐他汀10mg·d-1在国内的临床研究治疗中疗效和安全性均较好。

OBJECTIVE： To evaluate the lipid - regulatory efficacy and safety of rosuvastatin （10 mg ·d^-1） for Chinese population. METHODS： The pertinent literature comparing the serum blood lipid level before and after treatment with rosuvastatin （10 mg ·d^-1） between 2001 and 2008 were collected by retrieving Wanfang database, CNKI, Weipu electronic periodicals; and the data were given a meta - analysis using RevMan 4.2 software, meanwhile the safety of rosuvastatin was evaluated. RESULTS： A total of 346 patients were enrolled in 5 trials. After treatment with rosuvastatin （10 mg·d^-1）, the low density lipoproteincholesterol（LDL- C） was lowered by 1.71mmol·L^-1 on average; the total cholesterol （TC） was low-ered by 1.98 mmol·L^-1 on average; high density lipoprotein cholesterol（HDL- C） was increased by 0.17 mmol·L^-1 on average; and the level of triglyeride was lowered by 0.79mmol·L^-1 on average. A total of 54 adverse events were reported, and the adverse drug reactions manifested chiefly as upper respiratory infection, mild notalgia, debilitation and gastrointestinal upset. No severe side effects were reported. CONCLUSION： It has been confirmed by domestic clinical trials that rosuvastatin （10 mg ·d^-1） is safe and effective for Chinese population.